Conflict of interest: Nothing to report.
Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma†
Article first published online: 11 NOV 2010
Copyright © 2010 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 56, Issue 3, pages 491–494, March 2011
How to Cite
Aguilera, D. G., Goldman, S. and Fangusaro, J. (2011), Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr. Blood Cancer, 56: 491–494. doi: 10.1002/pbc.22868
- Issue published online: 10 JAN 2011
- Article first published online: 11 NOV 2010
- Manuscript Accepted: 13 SEP 2010
- Manuscript Received: 20 JUL 2010
Relapsed/refractory medulloblastoma (MB) has a poor outcome regardless of the treatment employed. Novel therapies are needed in an effort to improve survivals. We present two children with recurrent/refractory MB treated with bevacizumab and irinotecan both given every 2 weeks. One patient also received temozolamide. The first patient had stable disease and remains without progression after 30 months. The second patient had a near complete response that was sustained for 18 months. The regimen was well tolerated with minimal toxicity and provided prolonged progression-free survival in these two patients. Prospective clinical trials are needed to evaluate the effectiveness of this strategy. Pediatr Blood Cancer 2011;56:491–494. © 2010 Wiley-Liss, Inc.